A Cost-Benefit Analysis of VEGF-Inhibitor Therapy for Neovascular Age-Related Macular Degeneration in the United States
Gary C. Brown, Melissa M. Brown, Sara B. Rapuano, David S. Boyer
Topics & Concepts
RanibizumabAfliberceptMacular degenerationMedicineBevacizumabCombination therapyPopulationOphthalmologyInternal medicineChemotherapyEnvironmental healthRetinal Diseases and TreatmentsOphthalmology and Visual Impairment StudiesRetinopathy of Prematurity Studies